BMO Capital Downgrades 4D Molecular Therapeutics (FDMT) to Market Perform Jan 13, 2025 04:43AM
BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) Sep 19, 2024 08:14AM
BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) Aug 12, 2024 12:41PM
4D Molecular Therapeutics (FDMT) PT Lowered to $40 at BMO Capital Jul 18, 2024 08:56AM
BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) Jun 10, 2024 08:58AM


Jun 7, 2024 07:19AM BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
Mar 28, 2024 01:32PM 4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
Feb 5, 2024 01:04PM 4D Molecular Therapeutics (FDMT) PT Raised to $70 at BMO Capital, 'Strong PhII Data Support Our Top-Pick Thesis'